Impact of growth hormone-secreting pituitary adenoma on limbic system and its correlation with cognitive impairment
- PMID: 39220995
- PMCID: PMC11365443
- DOI: 10.1016/j.heliyon.2024.e35867
Impact of growth hormone-secreting pituitary adenoma on limbic system and its correlation with cognitive impairment
Abstract
Purpose: To assess the quantitative gray matter volume of the limbic system in growth hormone-secreting pituitary adenoma (GHPAs) patients and its correlation to cognitive function.
Method: 91 right-handed patients with pituitary adenomas were retrospectively included from the First Affiliated Hospital of Sun Yat-sen University -48 with GHPAs and 43 with non-functioning pituitary adenomas (NFPAs). Participants underwent serum hormone assessment, regular sellar MRI scanning with T1WI-MPRAGE. Cognitive function was gauged using MoCA and MMSE. Brain region auto-segmentation and gray matter volume calculation were conducted on the Brainsite platform.
Results: Compared to NFPAs patients, GHPAs patients had higher gray matter volume (758,285 vs 674,610 mm³, p < 0.001). No significant volumetric differences in both sides of limbic system gray matter while there were evident differences in the relative volumes of limbic system gray matter between groups. GHPAs patients scored lower on MOCA (24.0 (2.18) vs 25.1 (2.28), p < 0.031), with no difference in MMSE. We observed a significant correlation between the relative limbic volume and MOCA scales, while no evident correlation was found between relative limbic volume and serum hormone or tumor aggressiveness. Univariate and multivariate Logistic regression showed that hippocampus and limbic cortex (parahippocampal gyrus and internal olfactory area) of advantageous hemisphere correlated significantly with occurrence of mild cognitive impairment with the C-statistic reaching 0.90.
Conclusion: Patients with GHPAs show a relative decrease in limbic gray matter volume, especially in the hippocampus and limbic cortex of the dominant hemisphere, which is associated with mild cognitive impairment.
© 2024 The Authors.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures






Similar articles
-
Expression of the long non-coding RNA H19 and MALAT-1 in growth hormone-secreting pituitary adenomas and its relationship to tumor behavior.Int J Dev Neurosci. 2018 Jun;67:46-50. doi: 10.1016/j.ijdevneu.2018.03.009. Epub 2018 Mar 28. Int J Dev Neurosci. 2018. PMID: 29604339
-
Clinical characteristics and therapeutic outcomes of acromegalic patients with giant growth hormone-secreting pituitary adenomas: a single-center study of 67 cases.Pituitary. 2023 Dec;26(6):675-685. doi: 10.1007/s11102-023-01356-x. Epub 2023 Oct 17. Pituitary. 2023. PMID: 37847430
-
Next-generation sequencing of microRNAs reveals a unique expression pattern in different types of pituitary adenomas.Endocr J. 2019 Aug 29;66(8):709-722. doi: 10.1507/endocrj.EJ18-0487. Epub 2019 Apr 26. Endocr J. 2019. PMID: 31061247
-
Management of aggressive growth hormone secreting pituitary adenomas.Pituitary. 2017 Feb;20(1):169-178. doi: 10.1007/s11102-016-0781-7. Pituitary. 2017. PMID: 27987061 Review.
-
Management of growth hormone-secreting pituitary adenomas causing acromegaly: a practical review of surgical and multimodal management strategies for neurosurgeons.J Neurosurg. 2023 Nov 10;140(5):1285-1294. doi: 10.3171/2023.8.JNS221975. Print 2024 May 1. J Neurosurg. 2023. PMID: 37948697 Review.
References
-
- Tritos N.A., Miller K.K. Diagnosis and management of pituitary adenomas: a review. JAMA. 2023 Apr 25;329(16):1386–1398. - PubMed
-
- Park S.H., Ku C.R., Moon J.H., Kim E.H., Kim S.H., Lee E.J. Age- and sex-specific differences as predictors of surgical remission among patients with GHPAs. J. Clin. Endocrinol. Metabol. 2018;103(3):909–916. - PubMed
-
- Colao A., Grasso L.F.S., Giustina A., Melmed S., Chanson P., Pereira A.M., Pivonello R. GHPAs. Nat. Rev. Dis. Prim. 2019;5(1):20. - PubMed
-
- Melmed S. Pituitary-tumor endocrinopathies. N. Engl. J. Med. 2020;382(10):937–950. - PubMed
-
- Ershadinia N., Tritos N.A. Diagnosis and treatment of acromegaly: an update. Mayo Clin. Proc. 2022 Feb;97(2):333–346. - PubMed
LinkOut - more resources
Full Text Sources